Repeats-in-Toxin (RTX) proteins of Gram-negative bacteria are excreted through the type I secretion system (T1SS) that recognizes non-cleavable C-terminal secretion signals. These are preceded by arrays of glycine and aspartate-rich nonapeptide repeats grouped by four to eight β strands into blocks that fold into calcium-binding parallel β-roll structures. The β-rolls are interspersed by linkers of variable length and sequence and the organization of multiple RTX repeat blocks within large RTX domains remains unknown. Here we examined the structure and function of the RTX domain of Bordetella pertussis adenylate cyclase toxin (CyaA) that is composed of five β-roll RTX blocks. We show that the non-folded RTX repeats maintain the stability of the CyaA polypeptide in the Ca-depleted bacterial cytosol and thereby enable its efficient translocation through the T1SS apparatus. The efficacy of secretion of truncated CyaA constructs was dictated by the number of retained RTX repeat blocks and depended on the presence of extracellular Ca ions. We further describe the crystal structure of the RTX blocks IV-V of CyaA (CyaA) that consists of a contiguous assembly of two β-rolls that differs substantially from the arrangement of the RTX blocks observed in RTX lipases or other RTX proteins. These results provide a novel structural insight into the architecture of the RTX domains of large RTX proteins and support the "push-ratchet" mechanism of the T1SS-mediated secretion of very large RTX proteins.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2020.08.020DOI Listing

Publication Analysis

Top Keywords

rtx proteins
20
rtx
15
large rtx
12
rtx blocks
12
β-roll structures
8
secretion large
8
rtx repeat
8
repeat blocks
8
rtx domains
8
blocks
6

Similar Publications

Introduction: Standard treatment with cyclophosphamide (CP) or rituximab (RTX) is suboptimal. We adapted and used the low-dose regimen used in vasculitis (RTX 2 × 1000 mg, CP 1.5 mg/kg/d × 8 weeks, and prednisone [i.

View Article and Find Full Text PDF

The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment.

Front Immunol

December 2024

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

RTX was initially used for non-Hodgkin's lymphoma treatment and has been used in the clinical treatment of various autoimmune diseases as well as in antirejection and immune induction therapy for kidney transplant recipients. Following RTX treatment, the time for B cell regeneration varies among patients, but there is no unified recommendation for the frequency of B cell monitoring. This study aimed to investigate the clinical significance of periodic monitoring of peripheral blood B lymphocytes in individualized immunotherapy following rituximab (RTX) treatment in patients with different diseases.

View Article and Find Full Text PDF

BACKGROUND Rituximab (RTX) is a chimeric therapeutic monoclonal antibody that targets the CD20 molecule on B lymphocytes. RTX is approved for the treatment of rheumatoid arthritis (RA) in patients who do not respond to disease-modifying anti-rheumatic drugs (DMARDs) or other biologics. The purpose of this retrospective study was to report our experience with RTX treatment at a single center in Saudi Arabia between 2015 and 2022 in 52 patients with RA.

View Article and Find Full Text PDF

Berberine in combination with evodiamine ameliorates gastroesophageal reflux disease through TAS2R38/TRPV1-mediated regulation of MAPK/NF-κB signaling pathways and macrophage polarization.

Phytomedicine

December 2024

The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Department of Gastroenterology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210017, China. Electronic address:

Background: Gastroesophageal reflux disease (GERD) is a chronic condition of the digestive tract with limited therapeutic options. Bitter taste receptors (TAS2Rs) and transient receptor potential vanilloid-1 (TRPV1) are implicated in modulating inflammatory responses. Berberine (BBR) and evodiamine (EVO) are known to activate TAS2Rs and TRPV1, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • This study examined the stability of Sandoz rituximab biosimilar (SDZ-RTX) under various storage conditions, focusing on both in-use and out-of-fridge scenarios to ensure patient safety.
  • The researchers subjected two SDZ-RTX batches to long-term refrigeration followed by exposure to higher temperatures and humidity to simulate real-world storage situations.
  • Results indicated that SDZ-RTX maintained its physicochemical and biological quality, meeting strict acceptance criteria even after exposure to elevated temperatures, provided it was prepared in a sterile environment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!